)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Spermosens
Spermosens (SPERM) investor relations material
Spermosens Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Focus is shifting from development to go-to-market preparations, with partner discussions and clinical validation of JUNO-Checked progressing.
The Generation 3 study is on track; 86 patients had been tested, and sensor variation, shelf life and time to result improved.
Financial highlights
Q3 net sales were SEK 0; operating loss was SEK 2.377m versus SEK 2.356m in Q3 2025.
Q1–Q3 operating loss was SEK 7.338m versus SEK 7.080m; net loss was SEK 7.338m versus SEK 7.088m.
Q3 operating expenses were SEK 2.377m; R&D expenses fell to SEK 924k from SEK 1.995m, while G&A rose to SEK 1.445m from SEK 356k.
Q1–Q3 operating cash flow was negative SEK 7.303m versus negative SEK 4.755m; period-end cash was SEK 4.026m.
Outlook and guidance
Completion of Generation 3 validation and partner or license agreements are targeted for H2 2026; partner testing is planned for H1 2027.
Regulatory readiness and go-to-market preparations with partners are targeted for H2 2027, with partner-led commercial rollout planned for H1 2028.
Completion of the Generation 3 study by year-end remains the ambition, with flexibility to extend it for more data and refinement of routine-use test conditions.
The SEK 4.85m capital facility extends the cash runway into Q1 2027; TO6 warrants may provide additional funding.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Spermosens
- Clinical and commercial milestones are on track, with financial stability secured into 2027.SPERM
Status update - Clinical study recruitment surpassed expectations; capital facility secured to support commercialization.SPERMQ2 2026
- JUNO-Checked Gen 3 completed, clinical validation underway, and key partnerships advanced.SPERMQ1 2026
- Clinical validation and licensing targeted for 2026; strong partner interest and cost control.SPERMStatus update
- Patent wins, clinical validation, and strong cash position set stage for 2026 commercialization.SPERMQ4 2025
- Clinical validation, patent wins, and strong liquidity support next-gen product launch plans.SPERMQ3 2025
- Clinical validation and new funding support product development and market entry.SPERMQ2 2025
- Clinical study progress, strategic partnerships, and capital raises drive Spermosens' 2024 outlook.SPERMQ3 2024
- Operating loss narrows, but liquidity shortfall drives urgent capital raise and US expansion.SPERMQ2 2024
Next Spermosens earnings date
Q4 202611 Feb, 2027
Spermosens
Next Spermosens earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Spermosens AB is a Sweden-based medical technology company focused on fertility diagnostics. The company develops innovative solutions aimed at improving the understanding and treatment of male infertility. Spermosens’ technology centers on analyzing sperm function and compatibility with the egg, providing valuable insights for assisted reproductive treatments such as in vitro fertilization (IVF). The company is headquartered in Lund, Sweden, and its shares are listed on the Spotlight Stock Market.